Integration of CRISPR-Cas9 screens and multi-omics profiling reveals chromodomain helicase DNA binding protein 7-angiopoietin-1 as a novel multidrug resistance axis in acute myeloid leukemia
Dandan Yang , Tingting Zhang , Yang Yang , Dong Zhang , Zhiwei Zhou , Ning Wang , Jinting Fan , Chenghua Xu , Youyang Fang , Lichun Kang , Mingming Niu , Chunliang Li , Long Shen , Hong Wang
Interdisciplinary Medicine ›› 2025, Vol. 3 ›› Issue (5) : e70053
Integration of CRISPR-Cas9 screens and multi-omics profiling reveals chromodomain helicase DNA binding protein 7-angiopoietin-1 as a novel multidrug resistance axis in acute myeloid leukemia
Acute myeloid leukemia (AML) is a devastating hematological malignancy and one of the most prevalent forms of leukemia in adults. Despite recent advancements and approval of novel targeted therapies, drug resistance remains a formidable clinical challenge. In this study, we conducted an unbiased CRISPR-Cas9 knockout screen in AML cells to uncover novel mediators of resistance to the clinically approved FLT3 inhibitor gilteritinib. This screen identified chromodomain helicase DNA binding protein 7 (CHD7) as a new regulator of drug resistance. Strikingly, CHD7 loss not only conferred resistance to FLT3 inhibitors but also extended resistance to a broad range of therapeutics, including venetoclax and daunorubicin (DNR). Mechanistic investigations integrating transcriptomic and proteomic data revealed that CHD7 deletion upregulates angiopoietin-1 (ANGPT1), which drives resistance by activating the PI3K/AKT and MAPK/ERK signaling pathways. Significantly, genetic knockdown of ANGPT1 or pharmacological inhibition of its receptor TIE2 partially restored drug sensitivity in CHD7-deficient cells. Together, these findings identify the CHD7-ANGPT1 axis as a novel mechanism of multi-drug resistance in AML. Preclinical studies further suggest that combining targeted therapies with TIE2 inhibitors offers a promising strategy to overcome drug resistance in AML.
acute myeloid leukemia / ANGPT1 / CHD7 / drug resistance / gilteritinib / multi-omics / venetoclax
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
2025 The Author(s). Interdisciplinary Medicine published by Wiley-VCH GmbH on behalf of Nanfang Hospital, Southern Medical University.
/
| 〈 |
|
〉 |